Skip to main content
SpringerLink
Log in

Are Fluoroquinolones Superior Antibiotics for the Treatment of Community-Acquired Pneumonia?

  • Pleuropulmonary and Bronchial Infections (FW Arnold, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Various guidelines for the antibiotic treatment of community-acquired pneumonia (CAP) are presented that include fluoroquinolone antibiotics. The efficacy of current fluoroquinolone antibiotics in the treatment of CAP is summarized. Healthcare resource utilization and shortened duration of clinical symptoms have been shown in some, but not all of CAP trials utilizing fluoroquinolone antibiotics. Although evidence for both the clinical and microbiological efficacy of fluoroquinolone antibiotics is abundant, no convincing data demonstrates that they are superior to other standard antibiotics included in CAP guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest recently published are highlighted as: • Of importance •• Of major importance

  1. Schnoor M, Meyer T, Suttorp N, et al. Development and evaluation of an implementation strategy for the German guideline on community-acquired pneumonia. Qual Saf Health Care. 2010;19:498–502.

    Article  PubMed  CAS  Google Scholar 

  2. Menendez R, Torres A, Aspa J, et al. Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2010;46:543–58.

    Article  PubMed  Google Scholar 

  3. Mandell LA, Marrie TJ, Grossman RF, et al. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis. 2000;11:237–48.

    PubMed  CAS  Google Scholar 

  4. Miyashita N, Matsushima T, Oka M, Japanese Respiratory S. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45:419–28.

    Article  PubMed  Google Scholar 

  5. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138–80.

    Article  PubMed  CAS  Google Scholar 

  6. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.

    Article  PubMed  CAS  Google Scholar 

  7. British Thoracic Society Standards of Care Committee in collaboration w, endorsed by the Royal College of Physicians of London RCoGPBGSBLFBISBSfAC, Public Health Laboratory S. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56:iv1–iv64.

    Google Scholar 

  8. • Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66 Suppl 2:ii1–23. This is an excellent up to date set of guidelines based on the unique literature in children with community-acquired pneumonia..

    Article  PubMed  Google Scholar 

  9. • Spellberg B, Fleming TR, Gilbert DN. Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. Clin Infect Dis. 2008;47 Suppl 3:S105–107. This workshop stresses the need for future studies on community-acquired pneumonia focus on clinical designs that focus on superiority rather than non-inferiority..

    Article  PubMed  Google Scholar 

  10. Yoo BK, Triller DM, Yong CS, Lodise TP. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. Ann Pharmacother. 2004;38:1226–35.

    Article  PubMed  CAS  Google Scholar 

  11. Tillotson GS. Role of gemifloxacin in community-acquired pneumonia. Expert Rev Anti Infect Ther. 2008;6:405–18.

    Article  PubMed  CAS  Google Scholar 

  12. Lode HM, Schmidt-Ionas M, Stahlmann R. Gemifloxacin for community-acquired pneumonia. Expert Opin Investig Drugs. 2008;17:779–86.

    Article  PubMed  CAS  Google Scholar 

  13. Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;60:59–64.

    Article  PubMed  CAS  Google Scholar 

  14. Fogarty C, Torres A, Choudhri S, et al. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia. Int J Clin Pract. 2005;59:1253–9.

    Article  PubMed  CAS  Google Scholar 

  15. Garau J, Fritsch A, Arvis P, Read RC. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp. J Chemother. 2010;22:264–6.

    PubMed  CAS  Google Scholar 

  16. Borghi R, Piccini A, Barini E, et al. Upregulation of presenilin 1 in brains of sporadic, late-onset Alzheimer’s disease. J Alzheimers Dis. 2010;22:771–5.

    PubMed  CAS  Google Scholar 

  17. Ewig S, Hecker H, Suttorp N, et al. Moxifloxacin monotherapy versus ss-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia. J Infect. 2011;62:218–25.

    Article  PubMed  CAS  Google Scholar 

  18. An MM, Zou Z, Shen H, et al. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;36:58–65.

    Article  PubMed  CAS  Google Scholar 

  19. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest. 2003;124:526–35.

    Article  PubMed  Google Scholar 

  20. Signorovitch JE, Sheng Duh M, Sengupta A, et al. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. Curr Med Res Opin. 2010;26:355–63.

    Article  PubMed  CAS  Google Scholar 

  21. Schein J, Janagap-Benson C, Grant R, et al. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Curr Med Res Opin. 2008;24:895–906.

    Article  PubMed  CAS  Google Scholar 

  22. Lloyd A, Holman A, Evers T. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. Curr Med Res Opin. 2008;24:1279–84.

    Article  PubMed  CAS  Google Scholar 

  23. Friedman H, Song X, Crespi S, Navaratnam P. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia. Value Health. 2009;12:1135–43.

    Article  PubMed  Google Scholar 

  24. Ye X, Sikirica V, Schein JR, et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther. 2008;30:358–71.

    Article  PubMed  Google Scholar 

  25. Griffin AT, Peyrani P, Wiemken T, Arnold F. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. Int J Tuberc Lung Dis. 2010;14:495–9.

    PubMed  CAS  Google Scholar 

  26. Nakamura S, Yanagihara K, Izumikawa K, et al. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila. J Infect. 2009;59:222–4.

    Article  PubMed  Google Scholar 

  27. Sabria M, Pedro-Botet ML, Gomez J, et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest. 2005;128:1401–5.

    Article  PubMed  CAS  Google Scholar 

  28. Blazquez Garrido RM, Espinosa Parra FJ, Alemany Frances L, et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis. 2005;40:800–6.

    Article  PubMed  Google Scholar 

  29. Fogarty CM, Greenberg RN, Dunbar L, et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clin Ther. 2001;23:425–39.

    Article  PubMed  CAS  Google Scholar 

  30. Peterson J, Yektashenas B, Fisher AC. Levofloxacin for the treatment of pneumonia caused by Streptococcus pneumoniae including multidrug-resistant strains: pooled analysis. Curr Med Res Opin. 2009;25:559–68.

    Article  PubMed  CAS  Google Scholar 

  31. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med. 2006;100:2129–36.

    Article  PubMed  Google Scholar 

  32. Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Clin Ther. 2005;27:1251–9.

    Article  PubMed  CAS  Google Scholar 

  33. Bradley JS, Jackson MA. The use of systemic and topical fluoroquinolones. Pediatrics. 2011;128:e1034–45.

    Article  PubMed  Google Scholar 

  34. Wasserfallen JB, Erard V, Cometta A, et al. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J. 2004;24:644–8.

    Article  PubMed  Google Scholar 

  35. Samsa GP, Matchar DB, Harnett J, Wilson J. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial. Chest. 2005;128:3246–54.

    Article  PubMed  Google Scholar 

  36. Rittenhouse BE, Stinnett AA, Dulisse B, et al. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. Am J Manag Care. 2000;6:381–9.

    PubMed  CAS  Google Scholar 

  37. Frei CR, Jaso TC, Mortensen EM, et al. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Curr Med Res Opin. 2009;25:859–68.

    Article  PubMed  CAS  Google Scholar 

  38. •• Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ. 2008;179:1269–77. This meta-analysis demonstrates possible superiority of fluoroquinolone antibiotics in the treatment of community-acquired pneumonia when open-labelled trials are evaluated but not when blinded randomized trials are examined..

    Article  PubMed  Google Scholar 

  39. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009;CD002109.

  40. •• Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur Respir J. 2008;31:1068–76. This large meta-analysis of 13 studies and 4,314 adult patients with community-acquired pneumonia failed to demonstrate any advantage of specific antibiotic classes in mild to moderate cases..

    Article  PubMed  CAS  Google Scholar 

  41. Robenshtok E, Shefet D, Gafter-Gvili A, et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev. 2008;CD004418.

  42. Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175:1086–93.

    Article  PubMed  Google Scholar 

  43. File TM. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manag Care Pharm. 2009;15:S5–S11.

    PubMed  Google Scholar 

  44. Hess G, Hill JW, Raut MK, et al. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: results from a claims analysis. Adv Ther. 2010;27:743–55.

    Article  PubMed  CAS  Google Scholar 

  45. Restrepo MI, Frei CR. Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia. Am J Med. 2010;123:S39–46.

    Article  PubMed  Google Scholar 

  46. • Kabra SK, Lodha R, Pandey RM. Antibiotics for community acquired pneumonia in children. Cochrane Database Syst Rev. 2006;3:CD004874. This review stresses the importance of oral amoxicillin in the treatment pediatric community-acquired pneumonia..

    PubMed  Google Scholar 

  47. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med. 2004;98:708–20.

    Article  PubMed  CAS  Google Scholar 

  48. Lode H, File Jr TM, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther. 2002;24:1915–36.

    Article  PubMed  CAS  Google Scholar 

  49. File Jr TM, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother. 2007;60:112–20.

    Article  PubMed  CAS  Google Scholar 

  50. File Jr TM, Schlemmer B, Garau J, et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother. 2001;48:67–74.

    Article  PubMed  CAS  Google Scholar 

  51. Portier H, Brambilla C, Garre M, et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis. 2005;24:367–76.

    Article  PubMed  CAS  Google Scholar 

  52. Hoeffken G, Meyer HP, Winter J, Verhoef L. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med. 2001;95:553–64.

    Article  PubMed  CAS  Google Scholar 

  53. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J. 2003;21:135–43.

    Article  PubMed  CAS  Google Scholar 

  54. Jardim JR, Rico G, de la Roza C, et al. A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial. Arch Bronconeumol. 2003;39:387–93.

    Article  PubMed  CAS  Google Scholar 

  55. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest. 2001;119:185–95.

    Article  PubMed  CAS  Google Scholar 

  56. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. 2002;46:1746–54.

    Article  PubMed  CAS  Google Scholar 

  57. Welte T, Petermann W, Schurmann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis. 2005;41:1697–705.

    Article  PubMed  CAS  Google Scholar 

  58. Xu S, Xiong S, Xu Y, et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. J Huazhong Univ Sci Technolog Med Sci. 2006;26:421–4.

    Article  PubMed  CAS  Google Scholar 

  59. Katz E, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med. 2004;27:395–405.

    Article  PubMed  Google Scholar 

  60. Anzueto A, Niederman MS, Pearle J, et al. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis. 2006;42:73–81.

    Article  PubMed  CAS  Google Scholar 

  61. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med. 1999;16:748–63.

    Google Scholar 

  62. Kalbermatter V, Bagilet D, Diab M, Javkin E. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization. Med Clin (Barc). 2000;115:561–3.

    CAS  Google Scholar 

  63. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther. 2002;24:1292–308.

    Article  PubMed  CAS  Google Scholar 

  64. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis. 2004;38:S16.

    Article  CAS  Google Scholar 

  65. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998;30:397–404.

    Article  PubMed  CAS  Google Scholar 

  66. Erard V, Lamy O, Bochud PY, et al. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2004;23:82–8.

    Article  PubMed  CAS  Google Scholar 

  67. Carbon C, Ariza H, Rabie WJ, et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild–to–moderate community–acquired pneumonia. Clin Microbiol Infect. 1999;5:724–32.

    Article  CAS  Google Scholar 

  68. D’Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother. 2005;49:4035–41.

    Article  PubMed  Google Scholar 

  69. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37:752–60.

    Article  PubMed  CAS  Google Scholar 

  70. Lin TY, Lin SM, Chen HC, et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J. 2007;30:321–32.

    PubMed  Google Scholar 

  71. File Jr TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:1965–72.

    PubMed  CAS  Google Scholar 

  72. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther. 2002;24:736–51.

    Article  PubMed  CAS  Google Scholar 

  73. Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med. 2004;3:329–36.

    Article  PubMed  CAS  Google Scholar 

  74. van Rensburg DJ, Perng RP, Mitha IH, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010;54:4098–106.

    Article  PubMed  Google Scholar 

  75. Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther. 2010;35:195–200.

    Article  PubMed  CAS  Google Scholar 

  76. Dartois N, Castaing N, Gandjini H, Cooper A. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother. 2008;20 Suppl 1:28–35.

    PubMed  CAS  Google Scholar 

  77. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61:329–38.

    Article  PubMed  CAS  Google Scholar 

  78. Tanaseanu C, Milutinovic S, Calistru PI, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med. 2009;9:44.

    Article  PubMed  Google Scholar 

  79. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63:52–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. UC Davis, School of Medicine, 4150 V Street, Suite 3400, Sacramento, CA, 95817, USA

    Timothy E. Albertson, Brian M. Morrissey & Andrew L. Chan

  2. VA Northern California Health Care System, Mather, CA, USA

    Timothy E. Albertson, Brian M. Morrissey & Andrew L. Chan

Authors
  1. Timothy E. Albertson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian M. Morrissey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew L. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy E. Albertson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Albertson, T.E., Morrissey, B.M. & Chan, A.L. Are Fluoroquinolones Superior Antibiotics for the Treatment of Community-Acquired Pneumonia?. Curr Infect Dis Rep 14, 317–329 (2012). https://doi.org/10.1007/s11908-012-0251-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-012-0251-y

Keywords

Search

Navigation